Glytec Named Top Diabetes Management Platform for 2025

Recognition by Healthcare Tech Outlook underscores Glytec's leadership in hospital insulin management, clinical outcomes, and enterprise scalability

BOSTON, Sept. 16, 2025 /PRNewswire/ -- Glytec, the leading provider of an AI-powered diabetes platform for hospitals and health systems, today announced that Healthcare Tech Outlook named Glytec its Top Diabetes Management Platform for 2025. The annual award recognizes technologies that advance patient safety, streamline clinical workflows, and deliver measurable outcomes at scale.

"Earning Healthcare Tech Outlook's top honor validates the hard work our teams and hospital partners put in every day," said Patrick Cua, CEO of Glytec. "Glucommander is purpose‑built to help clinicians administer insulin more safely and easily, and this recognition reflects the difference it makes for patients across the continuum of care."

At the core of Glytec's cloud-based platform is Glucommander, the FDA-cleared insulin dosing software that helps clinicians personalize IV and subcutaneous insulin therapy. Surrounding capabilities, including workflow support tools, analytics, enterprise integration, and managed security, further reduce the IT burden for hospitals and help deliver safe, effective, and scalable glycemic management.

Why this recognition matters

• Comprehensive Solution: Glucommander supports IV insulin, subcutaneous insulin, and transitions, providing step-by-step guidance, alerts, and decision support tools to help streamline nursing workflows.
  
  
• Hospital and Patient Impact: More than one-third of hospitalized patients require insulin therapy during their stay. Each year, more than 2 million patients experience hypoglycemia-related adverse events in the hospital. According to the Agency for Healthcare Research and Quality (AHRQ), these events contribute to more than $8 billion in costs.
  
  
• Immediate Return on Investment: Glucommander helps achieve fewer hypoglycemic events, shorter hospital stays, reduced readmissions, and an average 6x–8x return on investment within the first 3 months.

Customer momentum

Community, academic, and IDN health systems use Glucommander® to elevate glycemic care in intensive care units, perioperative settings, medical‑surgical floors, and specialty areas. Recent initiatives include:

• Standardizing IV‑to‑SC (subcutaneous) transitions with clinical pathways supported by Glucommander's decision logic and rounding workflows.
  
  
• Empowering nurses and clinicians with simplified order sets, timers, alerts, guardrails, and real‑time insights.
  
  
• Leveraging analytics to track glycemic KPIs, drive financial returns, and sustain clinical improvements across sites.

About Glytec

Glytec's industry-leading, AI-driven technology platform, trusted by more than 400 hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing hospital length of stay and readmissions, and optimizing clinical workflows. Its flagship solution, Glucommander®, the first-ever FDA-cleared cloud-based insulin management software, integrates seamlessly with EHRs and provides advanced clinical decision support, workflow alerts, patient monitoring, and comprehensive analytics. Supported by industry awards and more than 100 patents and 100 peer-reviewed publications, Glytec is dedicated to improving care from the hospital to the home for patients, providers, and payers. For more information, visit www.glytec.com or follow Glytec on LinkedIn. 

About Healthcare Tech Outlook

Healthcare Tech Outlook is a technology publication that highlights innovative solutions and industry leaders advancing healthcare delivery. Its annual awards recognize companies pushing the boundaries of clinical excellence, operational efficiency, and patient experience.

Media Contact:
Glytec PR Team
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/glytec-named-top-diabetes-management-platform-for-2025-302558017.html

SOURCE Glytec, LLC